Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasms × lorlatinib × Clear all

Phase

Status

Terminated 2 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4 Sexual Dysfunction, Physiological 1 Recurrence 1 Non Small Cell Lung Cancer Metastatic 1 Neuroblastoma 1 Neoplasms 1 Neoplasm Metastasis 1 Glioma 1 Glioblastoma 1 Ganglioneuroblastoma 1 Eunuchism 1 Erectile Dysfunction 1 Diffuse Intrinsic Pontine Glioma 1 Astrocytoma 1 ALK-positive Non-small Cell Lung Cancer 1 ALK Positive Non-small Cell Lung Cancer 1

Interventions

Blood Specimen Collection 39 pembrolizumab 38 Bevacizumab 23 Surveys and Questionnaires 19 Standard of Care 18 Exercise 17 Carboplatin 17 Radiotherapy 16 Nivolumab 16 atezolizumab 14 Paclitaxel 14 Drug Therapy 13 Cyclophosphamide 13 Cisplatin 13 Fluorouracil 11 Pemetrexed 10 Leucovorin 10 Docetaxel 10 Dexamethasone 10 Cetuximab 10 olaparib 9 Trastuzumab 9 Temozolomide 9 Oxaliplatin 9 pertuzumab 8 Panitumumab 8 Observation 8 Irinotecan 8 Radiosurgery 7 Interviews as Topic 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡